Trial Profile
A Multi-center, Randomized, Open-label, Active-controlled Study to Compare the Safety, Tolerability and Effect on Glycemic Control of Taspoglutide Versus Insulin Glargine in Insulin-naive Type 2 Diabetic Patients Inadequately Controlled With Metformin and Sulphonylurea Combination Therapy.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Oct 2021
Price :
$35
*
At a glance
- Drugs Taspoglutide (Primary) ; Insulin glargine
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms EMERGE-5; T-EMERGE-5
- Sponsors Roche
- 31 Aug 2012 Results published in the Diabetic Medicine.
- 14 Oct 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 20 Sep 2010 Results were presented at the 46th Annual Meeting of the European Association for the Study of Diabetes.